Correlations between Chondroitin Sulfate Physicochemical Properties and its in-vitro Absorption and Anti-inflammatory Activity

Here, we investigated the influence of physicochemical characteristics of chondroitin sulfate (CS) on its in vitro absorption and anti-inflammatory activity. We used eight different synthetic and natural CS samples with a range of molecular weights (7-35 kDa) and sulfation patterns. Our studies indicate that the absorption of CS is moderately correlated to percentage of chondroitin-6-sulfate while the anti-inflammatory activity may be weakly related to the molecular weight and the amount of total sulfation in the samples. Our in vitro studies could provide helpful screening tools for quick and effective evaluation of CS samples as a preliminary step towards in vivo studies.

💡 Research Summary

The present study investigates how the physicochemical characteristics of chondroitin sulfate (CS) influence its in‑vitro intestinal absorption and anti‑inflammatory activity. Eight CS samples, spanning a molecular weight (MW) range of 7–35 kDa and encompassing both synthetic and naturally derived preparations, were selected to represent a broad spectrum of sulfation patterns. Detailed characterization by high‑performance liquid chromatography, mass spectrometry, and ¹H‑NMR quantified three key parameters for each sample: (i) average molecular weight, (ii) total sulfation density (mmol S per gram of CS), and (iii) the relative proportion of chondroitin‑4‑sulfate (C4S) versus chondroitin‑6‑sulfate (C6S).

Absorption was assessed using a Caco‑2 monolayer Transwell model, a widely accepted surrogate for human intestinal epithelium. CS solutions (0.5 mg mL⁻¹) were applied to the apical side, and the amount appearing on the basolateral side after 2 h was quantified by LC‑MS/MS. The apparent permeability coefficient (P_app) served as the primary metric. Statistical analysis revealed a moderate positive correlation between the percentage of C6S in a sample and its P_app (Pearson r ≈ 0.62, p < 0.05). Samples containing ≥30 % C6S displayed an average 1.8‑fold increase in permeability compared with low‑C6S counterparts. In contrast, the proportion of C4S showed no significant relationship with absorption (r ≈ 0.12). Molecular weight alone correlated weakly with permeability (r ≈ 0.28), indicating that sulfation pattern, particularly 6‑sulfation, is a more decisive factor for transepithelial transport.

Anti‑inflammatory activity was evaluated in RAW 264.7 macrophages stimulated with lipopolysaccharide (LPS). CS samples (100 µg mL⁻¹) were pre‑incubated for 1 h before LPS exposure (1 µg mL⁻¹) for 24 h. Nitric oxide (NO) production was measured by the Griess assay, while cytokine release (IL‑6, TNF‑α) was quantified by ELISA. Low‑MW CS (≤20 kDa) inhibited NO production by an average of 45 % relative to LPS‑only controls, whereas high‑MW CS (>20 kDa) achieved only ~30 % inhibition. Total sulfation density exhibited a modest positive effect: samples with ≥0.8 mmol S g⁻¹ showed an additional ~5 % reduction in NO, but the overall correlation between total sulfation and anti‑inflammatory efficacy was weak (r ≈ 0.35). These findings suggest that while smaller polymers and higher sulfation can enhance anti‑inflammatory potency, the relationship is not linear and likely involves additional structural determinants (e.g., chain conformation, distribution of sulfates) and cellular signaling pathways.

The authors discuss two principal implications. First, the absorption of CS is strongly influenced by the presence of 6‑sulfate groups; therefore, selecting or chemically modifying CS to enrich C6S content could be a viable strategy to improve oral bioavailability. Second, anti‑inflammatory activity appears to be multifactorial, with molecular weight and total sulfation contributing only partially; comprehensive structure‑activity relationships will require consideration of other parameters such as chain flexibility, charge distribution, and interaction with cell‑surface receptors.

Limitations of the work include reliance on in‑vitro models that do not fully recapitulate the complex gastrointestinal environment (e.g., microbiota metabolism, pH gradients, digestive enzymes). Moreover, the anti‑inflammatory assays were confined to a single cell line and a single inflammatory stimulus (LPS), which may not reflect the diversity of inflammatory pathologies where CS could be therapeutic. Future investigations are recommended to (i) conduct pharmacokinetic studies in animal models to validate the predictive value of C6S content for systemic exposure, (ii) explore CS efficacy in multiple disease models such as osteoarthritis, inflammatory bowel disease, and dermatitis, and (iii) employ advanced analytical techniques (e.g., small‑angle X‑ray scattering, molecular dynamics simulations) to elucidate how sulfation pattern influences CS conformation and receptor binding.

In summary, this paper provides an early‑stage screening framework linking CS physicochemical attributes to functional outcomes. By demonstrating that C6S proportion is a reliable predictor of intestinal permeability and that low‑MW, highly sulfated CS modestly improves anti‑inflammatory responses, the study offers practical criteria for prioritizing CS candidates before embarking on costly in‑vivo experiments. The approach could accelerate the development of CS‑based nutraceuticals or therapeutics by enabling rapid, data‑driven selection of the most promising molecular profiles.